Comparison of autologous and allogeneic stem cell transplantation for patients with Philadelphia chromosome-positive acute lymphoblastic leukemia
نویسندگان
چکیده
Objectives To analyze the outcomes of patients who received autologous stem cell transplantation (auto-SCT), matched sibling donor (MSD-SCT) and haploidentical (haplo-SCT) provide basis for choice method in Philadelphia chromosome-positive acute lymphoblastic leukemia (Ph+ ALL).Methods We retrospectively investigated 119 adult with Ph+ ALL our center. The overall survival (OS) rate, leukemia-free (LFS) cumulative incidence relapse (CIR) non-relapse mortality (NRM) rate impact achievement complete molecular response (CMR) within 3 months sustaining CMR up to (s3CMR) on were explored.Results estimated OS, LFS, CIR NRM rates at years not significantly different among three groups (p = 0.960, 0.917, 0.375 0.096, respectively). For 65 achieved s3CMR, there was no significant difference OS (84.5% vs 72.5% 100%, p 0.374), LFS (75.2% 64.5% 83.3%, 0.668), (17.2% 8.1% 16.7%, 0.583) (3.1% 23.4% 0%, 0.055) auto-SCT group, MSD-SCT group haplo-SCT group. However, did achieve recipients tended have higher (60% 33.2% 24.0%, 0.013) than allo-HSCT group.Conclusions Auto-SCT maintenance therapy after HSCT appears be an attractive treatment option especially those whose s3CMR kept transplantation. non-s3CMR patients, allogeneic may more effective from lower relapse.
منابع مشابه
allogeneic stem cell transplantation outcome in acute lymphoblastic leukemia patients
introduction: despite achievement to complete remission (cr) with current treatments and new multiple chemotherapeutic agents in acute lymphoblastic leukemia (all) patients, the majority of them still relapse during long-term follow-up. the use of post- remission therapy will reduce early relapse in these cases, but the best option is still debatable. patients and methods: in this retrospective...
متن کاملFeasibility of reduced-intensity allogeneic stem cell transplantation with imatinib in children with philadelphia chromosome-positive acute lymphoblastic leukemia.
Philadelphia chromosome-positive acute lymphoblastic leukemia (Ph + ALL) in children is one of the highest-risk ALL groups. Improved outcome in combination with imatinib has been reported. However, intensive chemotherapy or myeloablative conditioning followed by hematopoietic stem cell transplantation (HSCT) can be associated with significant adverse late effects. We report a case series of fiv...
متن کاملBone marrow transplantation for Philadelphia chromosome-positive acute lymphoblastic leukemia.
Philadelphia chromosome (Ph1)-positive acute lymphoblastic leukemia (ALL) has a poor prognosis when treated with conventional chemotherapy. We analyzed the outcome of 67 HLA-identical sibling bone marrow transplants (BMTs) for Ph1-positive ALL reported to the International Bone Marrow Transplant Registry (IBMTR). Twenty-one of 67 (31%) transplant recipients survived in continuous complete remis...
متن کاملIsolated skin relapse of Philadelphia chromosome-positive acute lymphoblastic leukemia after allogeneic stem cell transplant
Leukemia cutis is a rare entity diagnosed in only 1–3% of Tand B-cell acute lymphoblastic leukemia (ALL).1,2 Aleukemic leukemia cutis (ALC) is an even rarer diagnosis, occurring without leukemic cells in the blood or marrow, often preceding systemic disease.2,3 The Philadelphia chromosome (Ph) is one of the most common chromosomal abnormalities in adult B-ALL patients and is associated with poo...
متن کاملPhiladelphia chromosome-positive acute lymphoblastic leukemia: impact of imatinib treatment on remission induction and allogeneic stem cell transplantation.
Philadelphia chromosome-positive (Ph+) acute lymphoblastic leukemia (ALL) has been associated with the worst patient survival rates of the various acute leukemias. Imatinib mesylate is a novel therapeutic agent that targets the BCR-ABL tyrosine kinase, the molecular abnormality associated with Ph+ ALL. The combination of imatinib with chemotherapy has led to improved and durable treatment respo...
متن کاملذخیره در منابع من
با ذخیره ی این منبع در منابع من، دسترسی به آن را برای استفاده های بعدی آسان تر کنید
ژورنال
عنوان ژورنال: Hematology
سال: 2021
ISSN: ['1520-4391', '1520-4383']
DOI: https://doi.org/10.1080/16078454.2020.1868783